Building Essential Infrastructure for the Commercialization of Adoptive Cell Therapies

Adoptive Cell Therapy (ACT) is an innovative cancer treatment that activates a patient's immune system to destroy tumors. With a projected global market size of up to USD 16 billion by 2026, it is gaining significant attention. In particular, T-Cell Receptor (TCR) T-cell therapies targeting virus-associated solid tumors, such as cervical cancer, require a process of expanding the patient's T cells by a factor of hundreds. The NCT02821806 clinical trial, led by the National Cancer Institute (NCI), aims to establish a standardized donor platform by collecting large quantities of healthy peripheral blood mononuclear cells (PBMCs), which are essential raw materials for this rapid expansion process (Rapid Expansion Protocol, REP). This can be interpreted as a significant national infrastructure effort to reduce the variability of raw cells, a major obstacle to the commercialization of cell therapies, and to ensure consistent quality.

Securing High-Quality Supporting Cells Through Cell Collection

The core process of this study involves regularly collecting high-quality PBMCs from healthy volunteers through leukapheresis. This technique selectively collects white blood cells through centrifugation and returns the remaining blood components to the donor, minimizing the donor's physical burden while obtaining a high concentration of cells. The collected PBMCs undergo cryopreservation and are thawed when needed. After irradiation and pooling, they are used as supporting cells (Feeder Cells) to rapidly expand the patient's T cells by more than 100-fold. The industry expects that this standardized approach to securing supporting cells will significantly reduce the failure rate in the manufacturing and quality control (Chemistry, Manufacturing, and Controls, CMC) of cell therapies.

Strict Donor Screening and Long-Term Clinical Design

This observational study is conducted at the NIH Clinical Center's Department of Transfusion Medicine and aims to enroll 500 healthy adults aged 18 to 120. Participating donors can repeat cell collection every 21 days and must meet strict criteria, including a hemoglobin level of 12.5 g/dL (female) or 13.0 g/dL (male) and a negative infectious disease test within 30 days. The study, which began on August 8, 2016, is a long-term project with a primary completion date of March 1, 2030, and a final completion date of February 1, 2035. Its purpose is to establish a long-term banking system that can consistently supply healthy cells while ensuring the complete safety of donors.

Strong Synergy with Next-Generation Solid Tumor Pipelines

This donor platform is directly contributing to maximizing the production efficiency of next-generation cancer immunotherapy cell therapies being developed by the NCI's Scott M. Norberg research team. For example, various clinical pipelines, including HPV-16 E7-targeted TCR-T therapy (NCT02858310) and KK-LC-1-targeted solid tumor therapy (NCT05035407), are being produced based on this standardized PBMC bank, increasing production speed. Furthermore, it is expected to have a positive impact on the commercial clinical development of private companies such as T-Cure Bioscience, which acquired the global exclusive license for KK-LC-1 TCR-T from NCI, and Kite Pharma (Gilead Sciences, GILD) in the HPV-16 E7 TCR-T field, which are CRADA partners. Ultimately, this research will be a key stepping stone in significantly reducing the manufacturing costs of expensive cell therapies and dramatically improving production efficiency, thereby improving patient access to treatment.